Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 2/2015

01-03-2015 | Clinical Investigation

Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy

Authors: Tomoaki Higashiyama, Yasuhiro Nishida, Katsutaro Morino, Satoshi Ugi, Yoshihiko Nishio, Hiroshi Maegawa, Masahito Ohji

Published in: Japanese Journal of Ophthalmology | Issue 2/2015

Login to get access

Abstract

Purpose

To quantitatively evaluate the efficacy of methylprednisolone pulse therapy for extraocular muscle inflammation in thyroid-associated ophthalmopathy (TAO) using the short-tau inversion-recovery (STIR) technique of magnetic resonance imaging (MRI).

Methods

The signal intensities of the superior rectus (SR), inferior rectus (IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles were measured using the STIR images from 34 eyes of 17 patients with TAO before and after methylprednisolone pulse therapy and 19 eyes of 19 controls. The signal intensity ratio (SIR) of the signal intensity in muscles to that in brain white matter was calculated.

Results

The mean SIRs of the controls were 1.08 ± 0.26 in the SR, 1.32 ± 0.29 in the IR, 1.34 ± 0.19 in the LR, 1.47 ± 0.25 in the MR, and 1.28 ± 0.22 in the SO muscles. SIRs exceeding 2.0 were out of the normal range. The SIRs of the patients with TAO before treatment were 2.19 ± 0.64, 2.44 ± 0.58, 1.96 ± 0.43, 2.24 ± 0.47, and 1.91 ± 0.42, respectively, which was significantly (P < 0.001) higher than those of the controls; after treatment, the mean SIRs were 1.82 ± 0.57, 1.81 ± 0.49, 1.64 ± 0.35, 1.88 ± 0.43, and 1.54 ± 0.33, respectively, significantly (P < 0.001) lower in all muscles than those before treatment. However, the SIRs of some muscles remained over 2.0. Moreover, all cases that had deterioration of TAO had one or more muscles with a SIR exceeding 2.5 after treatment.

Conclusion

Extraocular muscle inflammation in TAO improved with treatment. However, inflammation in some muscles persisted after treatment, and a high SIR in the muscle after treatment suggested the risk of deterioration of TAO.
Literature
1.
2.
3.
4.
5.
6.
Dandona P, Marshall NJ, Bidey SP, Nathan A, Havard CW. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br Med J. 1979;1:374–6.CrossRefPubMedCentralPubMed
7.
Bigos ST, Nisula BC, Daniels GH, Eastman RC, Johnston HH, Kohler PO. Cyclophosphamide in the management of advanced Graves’ ophthalmopathy. A preliminary report. Ann Intern Med. 1979;90:921–3.CrossRef
8.
Weetman AP, McGregor AM, Ludgate M, Beck L, Mills PV, Lazarus JH, et al. Cyclosporin improves Graves’ ophthalmopathy. Lancet. 1983;2:486–9.CrossRefPubMed
9.
Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321:1353–9.CrossRefPubMed
10.
Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, et al. Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J. 1993;40:63–72.CrossRefPubMed
11.
Tagami T, Tanaka K, Sugawa H, Nakamura H, Miyoshi Y, Mori T, et al. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J. 1996;43:689–99.CrossRefPubMed
12.
Kauppinen-Mäkelin R, Karma A, Leinonen E, Löyttyniemi E, Salonen O, Sane T, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand. 2002;80:316–21.CrossRefPubMed
13.
Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves’ ophthalmopathy. Jpn J Ophthalmol. 2002;46:563–7.CrossRefPubMed
14.
Aktaran S, Akarsu E, Erbağci I, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61:45–51.CrossRefPubMed
15.
van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158:229–37.CrossRefPubMed
16.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639–44.CrossRefPubMedCentralPubMed
17.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.CrossRefPubMed
18.
Eidelberg D, Newton MR, Johnson G, MacManus DG, McDonald WI, Miller DH, et al. Chronic unilateral optic neuropathy: a magnetic resonance study. Ann Neurol. 1988;24:3–11.CrossRefPubMed
19.
Miller DH, Newton MR, van der Poel JC, du Boulay EP, Halliday AM, Kendall BE, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38:175–9.CrossRefPubMed
20.
Kermode AG, Moseley IF, Kendall BE, Miller DH, MacManus DG, McDonald WI. Magnetic resonance imaging in Leber’s optic neuropathy. J Neurol Neurosurg Psychiatry. 1989;52:671–4.CrossRefPubMedCentralPubMed
21.
Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid. 1992;2:299–305.CrossRefPubMed
22.
Hoh HB, Laitt RD, Wakeley C, Kabala J, Goddard P, Potts MJ, et al. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye (Lond). 1994;8:506–10.CrossRef
23.
Laitt RD, Hoh B, Wakeley C, Kabala J, Harrad R, Potts M, et al. The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol. 1994;67:244–7.CrossRefPubMed
24.
Bailey CC, Kabala J, Laitt R, Goddard P, Hoh HB, Potts MJ, et al. Magnetic resonance imaging in thyroid eye disease. Eye (Lond). 1996;10:617–9.CrossRef
25.
Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid eye disease. Eye (Lond). 2001;15:313–8.CrossRef
26.
Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005;56:20–4.CrossRefPubMed
27.
Rodríguez-González N, Pérez-Rico C, López-Para Giménez R, Arévalo-Serrano J, Del Amo García B, Calzada Domingo L, et al. Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves’ orbitopathy. Arch Soc Esp Oftalmol. 2011;86:351–7.CrossRefPubMed
28.
Tortora F, Prudente M, Cirillo M, Elefante A, Belfiore MP, Romano F. Diagnostic accuracy of short-time inversion recovery sequence in Graves’ Ophthalmopathy before and after prednisone treatment. Neuroradiology. 2014;56:353–61.CrossRefPubMed
29.
Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid. 2002;12:223–7.CrossRefPubMed
30.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.PubMed
31.
Gerlach M, Ferbert A. Pure eye muscle involvement in endocrine orbitopathy. Eur Neurol. 2008;60:67–72.CrossRefPubMed
Metadata
Title
Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy
Authors
Tomoaki Higashiyama
Yasuhiro Nishida
Katsutaro Morino
Satoshi Ugi
Yoshihiko Nishio
Hiroshi Maegawa
Masahito Ohji
Publication date
01-03-2015
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 2/2015
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-014-0365-x

Other articles of this Issue 2/2015

Japanese Journal of Ophthalmology 2/2015 Go to the issue

Clinical Investigation

Diagnostic performance and reproducibility of circumpapillary retinal nerve fiber layer thickness measurement in 10-degree sectors in early stage glaucoma

Clinical Investigation

Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling

Clinical Investigation

The role of entrapped cilia on the formation of lacrimal ductular cysts

Review

Occult macular dystrophy

Clinical Investigation

Virological and molecular biological evidence supporting herpes simplex virus type 1 corneal latency

Clinical Investigation

Intraocular pressure decreases after muscle union surgery for highly myopic strabismus